Cargando…
Safe and Successful Surgical Outcome in Persons with Hemophilia A with and without Inhibitors Treated with Emicizumab: A Large, Single Center, Real-World Experience
Emicizumab is a humanized recombinant bispecific antibody, bridging together activated factor IX (FIXa) and factor X (FX), thus mimicking the activity of FVIII in vivo. Emicizumab is designed for long-term prophylaxis in patients with severe hemophilia A with and without inhibitors. This approach pr...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10055920/ https://www.ncbi.nlm.nih.gov/pubmed/36983317 http://dx.doi.org/10.3390/jcm12062317 |
_version_ | 1785015997206364160 |
---|---|
author | Castaman, Giancarlo Linari, Silvia Pieri, Lisa Carulli, Christian Prosperi, Paolo Tonelli, Paolo Demartis, Francesco Fjerza, Rajmonda Attanasio, Monica Coppo, Mirella Salvianti, Francesca |
author_facet | Castaman, Giancarlo Linari, Silvia Pieri, Lisa Carulli, Christian Prosperi, Paolo Tonelli, Paolo Demartis, Francesco Fjerza, Rajmonda Attanasio, Monica Coppo, Mirella Salvianti, Francesca |
author_sort | Castaman, Giancarlo |
collection | PubMed |
description | Emicizumab is a humanized recombinant bispecific antibody, bridging together activated factor IX (FIXa) and factor X (FX), thus mimicking the activity of FVIII in vivo. Emicizumab is designed for long-term prophylaxis in patients with severe hemophilia A with and without inhibitors. This approach provides constant protection, with significant reduction in bleeding rate and improved quality of life. However, protection provided by emicizumab is not absolute, and clotting factor concentrates (FVIII, rFVIIa, aPCC) may be necessary for post-traumatic bleeding or surgery, with a potential thrombotic risk or difficulty in preventing bleeding. Real world evidence is still scanty, especially for managing major surgery. In this study, 75 surgeries were managed in 28 patients (27 major procedures in 15 patients and 48 minor procedures in 20 patients. In 17 patients without inhibitors, 30 minor surgeries were carried out by using FVIII in 5, with only a bleeding event, which was successfully treated with FVIII concentrate. Six major surgeries were uneventfully performed with FVIII concentrate. Eleven PWHA and high-titer inhibitors underwent 39 surgical procedures (18 minor and 21 major surgeries). Minor surgeries were mostly performed without prophylaxis with rFVIIa, with only a single bleeding complication. All 21 major surgeries were covered with a homogeneous protocol using rFVIIa. In four instances, bleeding complications occurred, treated with rFVIIa. Of them, a single patient only failed to respond and died because of an uncontrollable bleeding from a large ruptured retroperitoneal pseudotumor. Surgery in patients with emicizumab can be safely carried out with the use of appropriate replacement therapy protocols. |
format | Online Article Text |
id | pubmed-10055920 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100559202023-03-30 Safe and Successful Surgical Outcome in Persons with Hemophilia A with and without Inhibitors Treated with Emicizumab: A Large, Single Center, Real-World Experience Castaman, Giancarlo Linari, Silvia Pieri, Lisa Carulli, Christian Prosperi, Paolo Tonelli, Paolo Demartis, Francesco Fjerza, Rajmonda Attanasio, Monica Coppo, Mirella Salvianti, Francesca J Clin Med Article Emicizumab is a humanized recombinant bispecific antibody, bridging together activated factor IX (FIXa) and factor X (FX), thus mimicking the activity of FVIII in vivo. Emicizumab is designed for long-term prophylaxis in patients with severe hemophilia A with and without inhibitors. This approach provides constant protection, with significant reduction in bleeding rate and improved quality of life. However, protection provided by emicizumab is not absolute, and clotting factor concentrates (FVIII, rFVIIa, aPCC) may be necessary for post-traumatic bleeding or surgery, with a potential thrombotic risk or difficulty in preventing bleeding. Real world evidence is still scanty, especially for managing major surgery. In this study, 75 surgeries were managed in 28 patients (27 major procedures in 15 patients and 48 minor procedures in 20 patients. In 17 patients without inhibitors, 30 minor surgeries were carried out by using FVIII in 5, with only a bleeding event, which was successfully treated with FVIII concentrate. Six major surgeries were uneventfully performed with FVIII concentrate. Eleven PWHA and high-titer inhibitors underwent 39 surgical procedures (18 minor and 21 major surgeries). Minor surgeries were mostly performed without prophylaxis with rFVIIa, with only a single bleeding complication. All 21 major surgeries were covered with a homogeneous protocol using rFVIIa. In four instances, bleeding complications occurred, treated with rFVIIa. Of them, a single patient only failed to respond and died because of an uncontrollable bleeding from a large ruptured retroperitoneal pseudotumor. Surgery in patients with emicizumab can be safely carried out with the use of appropriate replacement therapy protocols. MDPI 2023-03-16 /pmc/articles/PMC10055920/ /pubmed/36983317 http://dx.doi.org/10.3390/jcm12062317 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Castaman, Giancarlo Linari, Silvia Pieri, Lisa Carulli, Christian Prosperi, Paolo Tonelli, Paolo Demartis, Francesco Fjerza, Rajmonda Attanasio, Monica Coppo, Mirella Salvianti, Francesca Safe and Successful Surgical Outcome in Persons with Hemophilia A with and without Inhibitors Treated with Emicizumab: A Large, Single Center, Real-World Experience |
title | Safe and Successful Surgical Outcome in Persons with Hemophilia A with and without Inhibitors Treated with Emicizumab: A Large, Single Center, Real-World Experience |
title_full | Safe and Successful Surgical Outcome in Persons with Hemophilia A with and without Inhibitors Treated with Emicizumab: A Large, Single Center, Real-World Experience |
title_fullStr | Safe and Successful Surgical Outcome in Persons with Hemophilia A with and without Inhibitors Treated with Emicizumab: A Large, Single Center, Real-World Experience |
title_full_unstemmed | Safe and Successful Surgical Outcome in Persons with Hemophilia A with and without Inhibitors Treated with Emicizumab: A Large, Single Center, Real-World Experience |
title_short | Safe and Successful Surgical Outcome in Persons with Hemophilia A with and without Inhibitors Treated with Emicizumab: A Large, Single Center, Real-World Experience |
title_sort | safe and successful surgical outcome in persons with hemophilia a with and without inhibitors treated with emicizumab: a large, single center, real-world experience |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10055920/ https://www.ncbi.nlm.nih.gov/pubmed/36983317 http://dx.doi.org/10.3390/jcm12062317 |
work_keys_str_mv | AT castamangiancarlo safeandsuccessfulsurgicaloutcomeinpersonswithhemophiliaawithandwithoutinhibitorstreatedwithemicizumabalargesinglecenterrealworldexperience AT linarisilvia safeandsuccessfulsurgicaloutcomeinpersonswithhemophiliaawithandwithoutinhibitorstreatedwithemicizumabalargesinglecenterrealworldexperience AT pierilisa safeandsuccessfulsurgicaloutcomeinpersonswithhemophiliaawithandwithoutinhibitorstreatedwithemicizumabalargesinglecenterrealworldexperience AT carullichristian safeandsuccessfulsurgicaloutcomeinpersonswithhemophiliaawithandwithoutinhibitorstreatedwithemicizumabalargesinglecenterrealworldexperience AT prosperipaolo safeandsuccessfulsurgicaloutcomeinpersonswithhemophiliaawithandwithoutinhibitorstreatedwithemicizumabalargesinglecenterrealworldexperience AT tonellipaolo safeandsuccessfulsurgicaloutcomeinpersonswithhemophiliaawithandwithoutinhibitorstreatedwithemicizumabalargesinglecenterrealworldexperience AT demartisfrancesco safeandsuccessfulsurgicaloutcomeinpersonswithhemophiliaawithandwithoutinhibitorstreatedwithemicizumabalargesinglecenterrealworldexperience AT fjerzarajmonda safeandsuccessfulsurgicaloutcomeinpersonswithhemophiliaawithandwithoutinhibitorstreatedwithemicizumabalargesinglecenterrealworldexperience AT attanasiomonica safeandsuccessfulsurgicaloutcomeinpersonswithhemophiliaawithandwithoutinhibitorstreatedwithemicizumabalargesinglecenterrealworldexperience AT coppomirella safeandsuccessfulsurgicaloutcomeinpersonswithhemophiliaawithandwithoutinhibitorstreatedwithemicizumabalargesinglecenterrealworldexperience AT salviantifrancesca safeandsuccessfulsurgicaloutcomeinpersonswithhemophiliaawithandwithoutinhibitorstreatedwithemicizumabalargesinglecenterrealworldexperience |